Janiczek Wealth Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Janiczek Wealth Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$822	Hold	20	–	–	﹤0.01%	950
2024 Q1	$934	Hold	20	–	–	﹤0.01%	949
2023 Q4	$957	Buy	+20	New	+$775	﹤0.01%	940
2023 Q3	–	Sell	-105	Closed	-$4.84K	–	1073
2023 Q2	$4.84K	Hold	105	–	–	﹤0.01%	659
2023 Q1	$4.01K	Hold	105	–	–	﹤0.01%	691
2022 Q4	$4.54K	Buy	+105	New	+$4.13K	﹤0.01%	668
2022 Q2	–	Sell	-13	Closed	-$1K	–	1053
2022 Q1	$1K	Buy	+13	New	+$904	﹤0.01%	890

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Janiczek Wealth Management's RARE Position: Q2 2024 in Review

Janiczek Wealth Management held its Ultragenyx Pharmaceutical (RARE) position steady in Q2 2024 at 20 shares worth $822. The position accounts for ﹤0.01% of the portfolio, ranked #950.

Janiczek Wealth Management first reported a position in RARE in Q1 2022 and has held it in 7 quarters since. The position peaked at $4.84K in Q2 2023. 274 funds tracked by Wall St. Rank hold RARE as of Q2 2024.

Janiczek Wealth Management held 20 shares of Ultragenyx Pharmaceutical worth $822 as of Q2 2024.
Janiczek Wealth Management left its Ultragenyx Pharmaceutical share count unchanged in Q2 2024.
Ultragenyx Pharmaceutical made up ﹤0.01% of Janiczek Wealth Management's portfolio in Q2 2024, its #950 holding.
Janiczek Wealth Management first reported a position in Ultragenyx Pharmaceutical in Q1 2022 and has held it in 7 quarters since.
Janiczek Wealth Management's Ultragenyx Pharmaceutical position peaked at $4.84K in Q2 2023.
274 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2024.

Based on Janiczek Wealth Management's 13F filing for Q2 2024, filed 25 Jul 2024.